• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

干扰素诱导跨膜蛋白 3(IFITM3)限制 SARS-CoV-2 在小鼠中的致死性。

Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice.

机构信息

Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.

Infectious Diseases Institute, The Ohio State University, Columbus, OH, USA.

出版信息

EMBO Rep. 2023 Apr 5;24(4):e56660. doi: 10.15252/embr.202256660. Epub 2023 Mar 7.

DOI:10.15252/embr.202256660
PMID:36880581
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10074051/
Abstract

Interferon-induced transmembrane protein 3 (IFITM3) is an antiviral protein that alters cell membranes to block fusion of viruses. Conflicting reports identified opposing effects of IFITM3 on SARS-CoV-2 infection of cells, and its impact on viral pathogenesis in vivo remains unclear. Here, we show that IFITM3 knockout (KO) mice infected with SARS-CoV-2 experience extreme weight loss and lethality compared to mild infection in wild-type (WT) mice. KO mice have higher lung viral titers and increases in inflammatory cytokine levels, immune cell infiltration, and histopathology. Mechanistically, we observe disseminated viral antigen staining throughout the lung and pulmonary vasculature in KO mice, as well as increased heart infection, indicating that IFITM3 constrains dissemination of SARS-CoV-2. Global transcriptomic analysis of infected lungs shows upregulation of gene signatures associated with interferons, inflammation, and angiogenesis in KO versus WT animals, highlighting changes in lung gene expression programs that precede severe lung pathology and fatality. Our results establish IFITM3 KO mice as a new animal model for studying severe SARS-CoV-2 infection and overall demonstrate that IFITM3 is protective in SARS-CoV-2 infections in vivo.

摘要

干扰素诱导跨膜蛋白 3(IFITM3)是一种抗病毒蛋白,可改变细胞膜以阻止病毒融合。有相互矛盾的报道指出 IFITM3 对 SARS-CoV-2 感染细胞的作用相反,其对体内病毒发病机制的影响尚不清楚。在这里,我们发现感染 SARS-CoV-2 的 IFITM3 敲除(KO)小鼠与野生型(WT)小鼠的轻度感染相比,体重减轻和死亡率极高。KO 小鼠的肺部病毒滴度更高,促炎细胞因子水平、免疫细胞浸润和组织病理学增加。从机制上看,我们观察到 KO 小鼠的肺部和肺血管中弥漫性病毒抗原染色,以及心脏感染增加,表明 IFITM3 限制了 SARS-CoV-2 的传播。感染肺部的全基因组转录组分析显示,与 WT 动物相比,KO 动物中与干扰素、炎症和血管生成相关的基因特征上调,突出了严重肺部病理和死亡之前肺基因表达程序的变化。我们的结果确立了 IFITM3 KO 小鼠作为研究严重 SARS-CoV-2 感染的新动物模型,并证明 IFITM3 在体内 SARS-CoV-2 感染中具有保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/ca60e6acaabb/EMBR-24-e56660-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/a09a839622ba/EMBR-24-e56660-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/2bb49b666e65/EMBR-24-e56660-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/790b0732d31d/EMBR-24-e56660-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/c60d9118d996/EMBR-24-e56660-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/ca60e6acaabb/EMBR-24-e56660-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/a09a839622ba/EMBR-24-e56660-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/2bb49b666e65/EMBR-24-e56660-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/790b0732d31d/EMBR-24-e56660-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/c60d9118d996/EMBR-24-e56660-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2857/10074051/ca60e6acaabb/EMBR-24-e56660-g002.jpg

相似文献

1
Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice.干扰素诱导跨膜蛋白 3(IFITM3)限制 SARS-CoV-2 在小鼠中的致死性。
EMBO Rep. 2023 Apr 5;24(4):e56660. doi: 10.15252/embr.202256660. Epub 2023 Mar 7.
2
Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice.干扰素诱导跨膜蛋白3(IFITM3)可降低新冠病毒对小鼠的致死率。
bioRxiv. 2021 Dec 23:2021.12.22.473914. doi: 10.1101/2021.12.22.473914.
3
Opposing activities of IFITM proteins in SARS-CoV-2 infection.干扰素诱导跨膜蛋白(IFITM)在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染中的相反作用
EMBO J. 2021 Feb 1;40(3):e106501. doi: 10.15252/embj.2020106501. Epub 2020 Dec 21.
4
Differential immunoregulation by human surfactant protein A variants determines severity of SARS-CoV-2-induced lung disease.人表面活性蛋白A变体的差异性免疫调节决定了SARS-CoV-2诱导的肺部疾病的严重程度。
Front Immunol. 2025 Apr 2;16:1462278. doi: 10.3389/fimmu.2025.1462278. eCollection 2025.
5
IFITM3 Inhibits SARS-CoV-2 Infection and Is Associated with COVID-19 Susceptibility.IFITM3 抑制 SARS-CoV-2 感染,并与 COVID-19 易感性相关。
Viruses. 2022 Nov 18;14(11):2553. doi: 10.3390/v14112553.
6
IFITM3 protects the heart during influenza virus infection.IFITM3 在流感病毒感染期间保护心脏。
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18607-18612. doi: 10.1073/pnas.1900784116. Epub 2019 Aug 26.
7
Opposing activities of IFITM proteins in SARS-CoV-2 infection.IFITM蛋白在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染中的相反作用。
bioRxiv. 2020 Aug 11:2020.08.11.246678. doi: 10.1101/2020.08.11.246678.
8
Impact of single nucleotide polymorphism of IL-27P28 rs153109 and IFITM3 rs12252 on susceptibility and severity of COVID-19 in Egyptian patients: a case control study.白细胞介素-27P28 rs153109单核苷酸多态性和干扰素诱导跨膜蛋白3 rs12252对埃及患者感染新型冠状病毒肺炎易感性及严重程度的影响:一项病例对照研究
Virol J. 2025 Mar 8;22(1):66. doi: 10.1186/s12985-025-02668-z.
9
The influence of IFITM3 polymorphisms on susceptibility to SARS-CoV-2 infection and severity of COVID-19.IFITM3 多态性对 SARS-CoV-2 感染易感性和 COVID-19 严重程度的影响。
Cytokine. 2021 Jun;142:155492. doi: 10.1016/j.cyto.2021.155492. Epub 2021 Mar 6.
10
Accelerated Adaptation of SARS-CoV-2 Variants in Mice Lacking IFITM3 Preserves Distinct Tropism and Pathogenesis.缺乏IFITM3的小鼠中SARS-CoV-2变体的加速适应性保留了不同的嗜性和致病性。
bioRxiv. 2025 Jan 29:2025.01.27.635150. doi: 10.1101/2025.01.27.635150.

引用本文的文献

1
Cardioprotective effects of AMPK activation in H1N1 influenza virus infection.AMPK激活在H1N1流感病毒感染中的心脏保护作用。
bioRxiv. 2025 Aug 28:2025.08.28.672931. doi: 10.1101/2025.08.28.672931.
2
Gasdermin E is Dispensable for H1N1 Influenza Virus Pathogenesis in Mice.Gasdermin E对小鼠甲型流感病毒发病机制无必需性。
bioRxiv. 2025 Jul 29:2025.07.29.667514. doi: 10.1101/2025.07.29.667514.
3
SARS-CoV-2 infection enhancement by amphotericin B: implications for disease management.两性霉素B增强严重急性呼吸综合征冠状病毒2感染:对疾病管理的启示

本文引用的文献

1
IFITM3 Inhibits SARS-CoV-2 Infection and Is Associated with COVID-19 Susceptibility.IFITM3 抑制 SARS-CoV-2 感染,并与 COVID-19 易感性相关。
Viruses. 2022 Nov 18;14(11):2553. doi: 10.3390/v14112553.
2
The P681H Mutation in the Spike Glycoprotein of the Alpha Variant of SARS-CoV-2 Escapes IFITM Restriction and Is Necessary for Type I Interferon Resistance.阿尔法变异株的刺突糖蛋白中的 P681H 突变逃避了 IFITM 的限制,并且是 I 型干扰素抵抗所必需的。
J Virol. 2022 Dec 14;96(23):e0125022. doi: 10.1128/jvi.01250-22. Epub 2022 Nov 9.
3
Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2.
J Virol. 2025 Jul 22;99(7):e0051925. doi: 10.1128/jvi.00519-25. Epub 2025 Jun 4.
4
Syntaxin-6 restricts SARS-CoV-2 infection by facilitating virus trafficking to autophagosomes.Syntaxin-6通过促进病毒转运至自噬体来限制新型冠状病毒2的感染。
J Virol. 2025 May 20;99(5):e0000225. doi: 10.1128/jvi.00002-25. Epub 2025 Apr 25.
5
variants point to a critical role in emergent virus infections.变体表明在新发病毒感染中起关键作用。
mBio. 2025 May 14;16(5):e0334724. doi: 10.1128/mbio.03347-24. Epub 2025 Apr 16.
6
Innate immune control of influenza virus interspecies adaptation via IFITM3.IFITM3 通过先天免疫控制流感病毒种间适应。
Nat Commun. 2024 Oct 30;15(1):9375. doi: 10.1038/s41467-024-53792-3.
7
A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist.全基因组 CRISPR 敲除筛选发现 PLCSR1 是新冠病毒进入细胞的内在屏障,近期的病毒变异体已进化出抵抗该屏障的能力。
PLoS Biol. 2024 Sep 24;22(9):e3002767. doi: 10.1371/journal.pbio.3002767. eCollection 2024 Sep.
8
IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN.IFN-λ 相对于 I 型 IFN ,特异性地促进 CD8 T 细胞对 SARS-CoV-2 的免疫应答。
JCI Insight. 2024 May 21;9(13):e171830. doi: 10.1172/jci.insight.171830.
9
The antiviral state of the cell: lessons from SARS-CoV-2.细胞的抗病毒状态:来自 SARS-CoV-2 的启示。
Curr Opin Immunol. 2024 Apr;87:102426. doi: 10.1016/j.coi.2024.102426. Epub 2024 May 24.
10
The Antiviral Activity of Interferon-Induced Transmembrane Proteins and Virus Evasion Strategies.干扰素诱导跨膜蛋白的抗病毒活性和病毒逃逸策略。
Viruses. 2024 May 6;16(5):734. doi: 10.3390/v16050734.
Rapalogs 下调固有免疫并促进 SARS-CoV-2 的细胞进入。
J Clin Invest. 2022 Dec 15;132(24):e160766. doi: 10.1172/JCI160766.
4
IFITM3 restricts virus-induced inflammatory cytokine production by limiting Nogo-B mediated TLR responses.IFITM3 通过限制 Nogo-B 介导的 TLR 反应来限制病毒诱导的炎症细胞因子产生。
Nat Commun. 2022 Sep 8;13(1):5294. doi: 10.1038/s41467-022-32587-4.
5
Long-term cardiac pathology in individuals with mild initial COVID-19 illness.轻症 COVID-19 患者的长期心脏病理学变化。
Nat Med. 2022 Oct;28(10):2117-2123. doi: 10.1038/s41591-022-02000-0. Epub 2022 Sep 5.
6
Influenza virus replication in cardiomyocytes drives heart dysfunction and fibrosis.流感病毒在心肌细胞中的复制导致心脏功能障碍和纤维化。
Sci Adv. 2022 May 13;8(19):eabm5371. doi: 10.1126/sciadv.abm5371. Epub 2022 May 11.
7
SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells.SARS-CoV-2 关切变种劫持 IFITM2 以在人肺细胞中高效复制。
J Virol. 2022 Jun 8;96(11):e0059422. doi: 10.1128/jvi.00594-22. Epub 2022 May 11.
8
Long-term cardiovascular outcomes of COVID-19.COVID-19 长期心血管后果。
Nat Med. 2022 Mar;28(3):583-590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7.
9
Association between the interferon-induced transmembrane protein 3 gene () rs34481144 / rs12252 haplotypes and COVID-19.干扰素诱导跨膜蛋白3基因()rs34481144 / rs12252单倍型与2019冠状病毒病的关联。
Curr Res Virol Sci. 2021;2:100016. doi: 10.1016/j.crviro.2021.100016. Epub 2021 Nov 29.
10
CCR2 Signaling Restricts SARS-CoV-2 Infection.CCR2 信号限制 SARS-CoV-2 感染。
mBio. 2021 Dec 21;12(6):e0274921. doi: 10.1128/mBio.02749-21. Epub 2021 Nov 9.